Related Experiment Video

Updated: Jun 27, 2026

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients
09:09

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients

Published on: April 3, 2026

[The role of activator protein-1 in unstable coronary atherosclerotic changes]

Gui-Hua Miao1, Li-Xia Yang, Feng Qi

  • 1Department of Cardiology, Kunming General Hospital of Chengdu Military Command, Kunming 650032, China.

Zhonghua Nei Ke Za Zhi
|November 28, 2008
PubMed

Insights

Activator protein-1 (AP-1) levels are significantly elevated in patients with coronary heart disease (CHD). Higher AP-1 levels correlate with more severe coronary atherosclerotic changes and plaque instability, suggesting AP-1 as a predictor of disease progression.

Area of Science:

  • Molecular biology
  • Cardiovascular research
  • Biochemistry

Context:

  • Coronary heart disease (CHD) involves atherosclerotic plaque development.
  • The role of specific transcription factors, like activator protein-1 (AP-1), in CHD pathogenesis is not fully understood.
  • Investigating AP-1's involvement may reveal new insights into plaque stabilization and progression.

Purpose:

  • To examine the relationship between activator protein-1 (AP-1) and coronary atherosclerotic changes.
  • To determine if AP-1 plays a role in the stabilization of atherosclerotic plaques in patients with CHD.
  • To assess AP-1 levels in relation to different stages and severities of coronary artery disease.

Summary:

  • This study measured Phospho-c-Jun, a component of AP-1, in 142 patients (107 with CHD, 35 controls) using ELISA.
  • AP-1 levels were significantly higher in CHD patients compared to controls and increased with disease severity (ACS vs. SAP, type C vs. A, severe vs. light stenosis).
  • Results indicate a strong correlation between elevated AP-1 and advanced coronary atherosclerosis.

Impact:

  • Findings suggest a significant association between AP-1 and the progression of coronary atherosclerosis.
  • AP-1 may serve as a potential biomarker for predicting the progression and stability of atherosclerotic plaques.
  • This research could inform future therapeutic strategies targeting AP-1 in cardiovascular disease management.
Abstract

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...